Background And Objectives: Evidence of immune response to COVID-19 vaccine in psoriasis patients on biological agents is lacking. This study aimed to evaluate SARS-CoV-2 antibody levels following vaccination with CoronaVac or Pfizer/BioNTech mRNA in patients using biological agents or methotrexate, high-titer antibody levels achievement rate, and impact of medications on immunogenicity.
Methods: This noninterventional, prospective cohort study included 89 patients and 40 controls vaccinated with two doses of inactivated (CoronaVac) or Pfizer/BioNTech mRNA vaccines. Anti-spike and neutralising antibodies were analysed before and three to six weeks after the second dose. Adverse effects and symptomatic COVID-19 were assessed.
Results: Median anti-spike and neutralising antibody titers after CoronaVac were significantly lower in patients than controls (57.92 U/mL vs 125.4 U/mL, and 1/6 vs 1/32, respectively, p < 0.05). Patients were less likely to achieve high-titer anti-spike antibody levels (25.6 % vs 50 %). Infliximab was associated with attenuated vaccine response. Pfizer/BioNTech vaccine induced comparable median anti-spike (2,080 U/mL vs 2,976.5 U/mL,) and neutralising antibody levels (1/96 vs 1/160) in patients and controls, respectively (p > 0.05). High-titer anti-spike and neutralising antibodies development rates were comparable among patients and controls (95.2 % vs 100 %, and 30.4 % vs 50.0 %, respectively, p > 0.05). Nine (10.1 %) COVID-19 cases- all mild - were identified. Psoriasis flare was seen in 6.74 %, mostly after Pfizer/BioNTech vaccine.
Conclusion: Psoriasis patients treated with biological agents and methotrexate developed similar response to mRNA vaccine but weaker response to inactivated vaccine. Infliximab reduced response to the inactivated vaccine. Adverse effects were more frequent with mRNA vaccine, but none was severe.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239265 | PMC |
| http://dx.doi.org/10.1016/j.vaccine.2023.05.052 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A rare long-term side effect of COVID-19 vaccines: Symmetrical drug-related intertriginous and flexural exanthema-like reaction SDRIFE and potential immunogens for delayed type hypersensitivity reactions.
Int Immunopharmacol
January 2025
Ege University, Faculty of Medicine, Department of Pulmonary Medicine, Immunology and Allergy, Laboratory of Occupational/Environmental Respiratory Diseases and Asthma, 35100 Izmir, Türkiye; EgeSAM (Ege University Translational Pulmonary Research Center), 35100 Izmir, Türkiye. Electronic address:
Background: Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) is an important clinical entity that is rare and may develop with a Type IV delayed type hypersensitivity immune response to drug antigens. The incidence and characteristics of SDRIFE attributed to COronaVIrus Disease of 2019 (COVID-19) vaccines remain unclear, this issue requires further elucidation.
Objective: We aim to investigate the vaccine-related-SDRIFE and potential immunogens of COVID-19 vaccines through a literature review accompanied by a real case.
Heterologous Versus Homologous COVID-19 Boosters: Immune Response Outcomes in Renal Transplant Recipients.
J Med Virol
November 2024
Department of Nephrology, Gazi University Faculty of Medicine, Ankara, Turkey.
Article Synopsis
- * Out of 90 RTR participants, the median antibody level was 16.7 AU/mL at 42 days post-first dose, with 60% showing positive serology; mycophenolic acid (MFA) and ACE inhibitors were found to decrease seropositivity.
- * Patients who received the Pfizer/BioNTech booster had better antibody levels and lower COVID-19 infections compared to those with the CoronaVac/Sinovac booster, indicating that heterologous vaccination is more effective for RTRs.
Booster Vaccination with BNT162b2 Improves Cellular and Humoral Immune Response in the Pediatric Population Immunized with CoronaVac.
Vaccines (Basel)
August 2024
Subdepartamento Innovación y Desarrollo, Departamento Agencia Nacional de Dispositivos Médicos, Innovación y Desarrollo, Instituto de Salud Pública de Chile, Santiago 7780050, Chile.
The SARS-CoV-2 Omicron variant and its sublineages continue to cause COVID-19-associated pediatric hospitalizations, severe disease, and death globally. BNT162b2 and CoronaVac are the main vaccines used in Chile. Much less is known about the Wuhan-Hu-1 strain-based vaccines in the pediatric population compared to adults.
View Article and Find Full Text PDFExploring SARS-CoV-2 infection and vaccine-induced immunity in chronic myeloid leukemia patients: insights from real-world data in Brazil and the United States.
Leuk Lymphoma
November 2024
Centro de Hematologia e Hemoterapia (Hemocentro-UNICAMP), Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil.
This study investigates COVID-19 outcomes and immune response in chronic myeloid leukemia (CML) patients post-SARS-CoV-2 vaccination, comparing effectiveness of various vaccine options. Data from 118 CML patients (85 in Brazil, 33 in the US) showed similar infection rates prior (14% Brazil, 9.1% US) and post-vaccination (24.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!